Cipla has formally submitted an abbreviated new drug application to the US Food and Drug Administration for the Indian firm’s generic version of GlaxoSmithKline’s Advair Diskus (fluticasone/salmeterol).
The application – submitted in 100mcg/50mcg, 250mcg/50mcg and 500mcg/50mcg strengths – comes as the FDA is still considering Hikma’s proposed...




